P. Gómez Pardo

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet · 2023 · 363 citations · Full text

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · Journal of Clinical Oncology · 2022 · 275 citations · Full text

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

Sònia Pernas, Miguel Martín, Peter A. Kaufman et al. · The Lancet Oncology · 2018 · 133 citations

Breast Oncology, Oncology, Medicine +8

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

Giuseppe Curigliano, P. Gómez Pardo, Funda Meric‐Bernstam et al. · The Breast · 2016 · 132 citations · Full text

Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · Journal of Clinical Oncology · 2022 · 110 citations

Breast Oncology, Primary Results, Cancer Management +17